{
    "ticker": "EVLO",
    "name": "Evolus, Inc.",
    "description": "Evolus, Inc. is a performance beauty company focused on delivering innovative aesthetic products for consumers and physicians. Founded in 2012 and headquartered in Newport Beach, California, Evolus is best known for its flagship product, Jeuveau, which is an FDA-approved injectable neurotoxin designed for aesthetic use. Jeuveau is primarily used to temporarily improve the appearance of frown lines between the eyebrows, catering to a growing demand in the beauty and aesthetics market. The company strives to challenge the traditional norms of the aesthetics industry by providing high-quality products at an accessible price point, thereby enhancing the consumer experience. Evolus emphasizes its commitment to safety, efficacy, and innovation in its product offerings. The company\u2019s mission is to empower consumers to express their individual beauty confidently, while also ensuring that physicians have the tools they need to deliver optimal aesthetic outcomes. As a relatively young player in the industry, Evolus is leveraging digital marketing strategies to connect with consumers and healthcare professionals, establishing a strong brand presence in the highly competitive market of aesthetic treatments.",
    "industry": [
        "Aesthetics",
        "Pharmaceuticals"
    ],
    "headquarters": "Newport Beach, California, USA",
    "founded": "2012",
    "website": "https://www.evolus.com",
    "ceo": "David Moatazedi",
    "social_media": {
        "twitter": "https://twitter.com/evolusinc",
        "linkedin": "https://www.linkedin.com/company/evolus-inc/"
    },
    "investor_relations": "https://investors.evolus.com",
    "key_executives": [
        {
            "name": "David Moatazedi",
            "position": "CEO"
        },
        {
            "name": "Michael L. R. A. G. H. S. P. S. K. K. M. P. C. M. M. C. D. S. W.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Injectables",
            "products": [
                "Jeuveau"
            ]
        }
    ],
    "seo": {
        "meta_title": "Evolus, Inc. | Innovative Aesthetic Solutions",
        "meta_description": "Explore Evolus, Inc., a leader in aesthetic products focused on enhancing beauty through innovation. Discover our flagship product, Jeuveau, and our commitment to quality and consumer empowerment.",
        "keywords": [
            "Evolus",
            "Aesthetic Products",
            "Jeuveau",
            "Beauty Industry",
            "Injectables"
        ]
    },
    "faq": [
        {
            "question": "What is Evolus known for?",
            "answer": "Evolus is known for its innovative aesthetic product, Jeuveau, an injectable neurotoxin for cosmetic use."
        },
        {
            "question": "Who is the CEO of Evolus?",
            "answer": "David Moatazedi is the CEO of Evolus, Inc."
        },
        {
            "question": "Where is Evolus headquartered?",
            "answer": "Evolus is headquartered in Newport Beach, California, USA."
        },
        {
            "question": "What is Jeuveau?",
            "answer": "Jeuveau is an FDA-approved injectable neurotoxin used to temporarily improve the appearance of frown lines."
        },
        {
            "question": "When was Evolus founded?",
            "answer": "Evolus was founded in 2012."
        }
    ],
    "competitors": [
        "ALLERGAN",
        "MHK",
        "HZO"
    ],
    "related_stocks": [
        "CANF",
        "HUM",
        "NTRB",
        "EHTH"
    ]
}